Medication info
Dapalil Tablet 10 mg (Dapagliflozin Propanediol Hydrate)

Dapalil Tablet 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
Yellow, bi-convex, diamond-shaped film-coated tablet
Packaging
PTP - 28 tablets/box [28 tablets (7 tablets/PTP x 4)], bottle - 30 tablets/bottle, bottle - 300 tablets/bottle
Approval status
Active

MFDS item code 202201843 · Approved 2022.05.04 · Insurance code 654005900

Summary

Main use
Improves blood glucose levels in type 2 diabetes and prevents worsening of chronic heart failure and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medication is 10mg once daily for monotherapy and add-on combination therapy with other antihyperglycemic agents, such as insulin. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous history of antidiabetic drug treatment, the recommended initial dose of this medication when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medication is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medication to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medication is not recommended in patients with chronic heart failure or chronic kidney disease. - Patients receiving dialysis: Do not administer this medication. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medication may be administered orally once daily at any time of day, with or without food. Tablets should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose levels in type 2 diabetes and prevents worsening of chronic heart failure and chronic kidney disease

  • Type 2 diabetes
  • glycemic control disorders
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • reduced glomerular filtration rate
  • end-stage kidney disease
View approved original text

This medication is used together with diet and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. Additionally, it helps reduce the risk of death and hospitalization due to cardiovascular disease in patients with chronic heart failure. It also plays a role in reducing the decline in kidney function and the risk of cardiovascular death in patients with chronic kidney disease. This drug is used in combination with standard treatments appropriate for each condition, making it effective for comprehensive management of the patient's status. Therefore, it is used in the treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medication is 10mg once daily for monotherapy and add-on combination therapy with other antihyperglycemic agents, such as insulin. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous history of antidiabetic drug treatment, the recommended initial dose of this medication when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medication is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medication to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medication is not recommended in patients with chronic heart failure or chronic kidney disease. - Patients receiving dialysis: Do not administer this medication. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medication may be administered orally once daily at any time of day, with or without food. Tablets should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be administered to certain patients. For example, it should not be used in individuals who are allergic to the active ingredient or excipients, patients with type 1 diabetes or diabetic ketoacidosis, individuals with lactose intolerance or certain genetic metabolic disorders, and patients undergoing dialysis. Caution should be exercised when administering this medication to patients with reduced fluid volume or impaired renal function. This drug can lower blood pressure or affect renal function, so elderly patients or those taking diuretics need to be monitored more closely. Evaluate fluid status and renal function thoroughly before administration, and continuously monitor blood pressure and renal function during treatment. This medication may cause various side effects including genital infections, urinary tract infections, hypoglycemia, reduced fluid volume, and diabetic ketoacidosis. Genital infections may occur more frequently in women, so immediate treatment should be sought if symptoms arise. The risk of hypoglycemia may be increased when used in conjunction with insulin or sulfonylureas, so dosage adjustments may be necessary when using these agents together. Pregnant and breastfeeding women are advised not to use this medication. If pregnancy is confirmed, treatment should be discontinued immediately, and it is safe to avoid this medication during breastfeeding. Elderly patients or those with impaired renal function are at higher risk of side effects from this drug and should be more cautious. Additionally, this medication may yield a positive result in urine glucose tests, so take this into account during blood glucose monitoring. This drug may interact with other medications, so especially when taking diuretics, insulin, or sulfonylureas, consultation with a physician or pharmacist is necessary. Patients taking lithium should have their blood lithium levels checked more frequently. In case of overdose, there are no specific antidotes, so appropriate treatment based on the patient's condition is essential. Finally, the safety and efficacy of this medication in children have not been established, so it is preferable not to use it in this population. When storing the drug, keep it out of reach of children and store it in its original container to maintain quality.

Side effects

vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased blood volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, elevated hematocrit, decreased renal creatinine clearance at the start of treatment, dyslipidemia, elevated serum creatinine at the start of treatment, elevated blood urea, weight loss, rash, angioedema, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, gastroesophageal reflux disease, upper abdominal pain, diverticulitis, intestinal perforation, acute pancreatitis, chronic pancreatitis, hyperglycemia, paresthesia, cerebral infarction, nerve compression, weakness, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, biliary stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory loss, headache, nasopharyngitis, upper respiratory infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like syndrome, chest pain, fatigue, hunger, vaginal discharge, pruritus, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and ensure safe use.

Appearance and packaging

Appearance

Yellow, bi-convex, diamond-shaped film-coated tablet

Package unit

PTP - 28 tablets/box [28 tablets (7 tablets/PTP x 4)], bottle - 30 tablets/bottle, bottle - 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.